MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of “Hold” by Brokerages

MoonLake Immunotherapeutics (NASDAQ:MLTX) has received an average rating of “Hold” from the fifteen analysts that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $30.25.

Several brokerages have recently weighed in on MLTX. Weiss Ratings restated a “sell (d-)” rating on shares of MoonLake Immunotherapeutics in a report on Wednesday, October 8th. HC Wainwright reduced their price objective on MoonLake Immunotherapeutics from $30.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, November 21st. Wolfe Research cut shares of MoonLake Immunotherapeutics from an “outperform” rating to an “underperform” rating in a research report on Tuesday, September 30th. Jefferies Financial Group downgraded shares of MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $8.00 target price on the stock. in a research note on Monday, September 29th. Finally, Citigroup lowered shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a report on Wednesday, October 29th.

MoonLake Immunotherapeutics Trading Down 0.3%

Shares of MLTX opened at $13.83 on Friday. MoonLake Immunotherapeutics has a 52-week low of $5.95 and a 52-week high of $62.75. The company has a quick ratio of 8.50, a current ratio of 8.50 and a debt-to-equity ratio of 0.25. The firm’s fifty day moving average is $12.48 and its two-hundred day moving average is $33.61. The stock has a market cap of $888.30 million, a PE ratio of -4.17 and a beta of 1.21.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.21). During the same period in the previous year, the firm earned ($0.56) EPS. Research analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.

Insider Activity at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, insider Kristian Reich sold 130,000 shares of MoonLake Immunotherapeutics stock in a transaction on Monday, December 8th. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00. Following the sale, the insider owned 72,908 shares in the company, valued at $1,099,452.64. The trade was a 64.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Bihua Chen sold 6,494,151 shares of the company’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $7.21, for a total value of $46,822,828.71. Following the completion of the transaction, the insider directly owned 2,000,000 shares in the company, valued at approximately $14,420,000. This trade represents a 76.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 6,902,886 shares of company stock worth $52,850,547. Insiders own 12.02% of the company’s stock.

Institutional Trading of MoonLake Immunotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Schonfeld Strategic Advisors LLC purchased a new position in MoonLake Immunotherapeutics during the third quarter worth about $6,922,000. Two Sigma Investments LP purchased a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at approximately $3,257,000. Vestal Point Capital LP lifted its holdings in shares of MoonLake Immunotherapeutics by 175.0% in the 2nd quarter. Vestal Point Capital LP now owns 550,000 shares of the company’s stock worth $25,960,000 after acquiring an additional 350,000 shares during the last quarter. Balyasny Asset Management L.P. grew its stake in shares of MoonLake Immunotherapeutics by 436.8% in the second quarter. Balyasny Asset Management L.P. now owns 423,170 shares of the company’s stock valued at $19,974,000 after buying an additional 344,335 shares in the last quarter. Finally, Millennium Management LLC grew its position in MoonLake Immunotherapeutics by 3,343.2% in the 1st quarter. Millennium Management LLC now owns 344,320 shares of the company’s stock valued at $13,453,000 after acquiring an additional 334,320 shares in the last quarter. 93.85% of the stock is currently owned by hedge funds and other institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.